Awards

$298K

GPCR antagonists as anti-Ebola virus entry inhibitors

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 08/01/16 - 07/31/17
PI: LIJUN RONG

? DESCRIPTION (provided by applicant): Ebola (EBOV) and Marburg (MARV) viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of 4-14 days. Because of the safety concerns, these viruses are designated as biosafety level 4 agents. Currently there i...

$304K

Novel beta-lactams as inhibitors of ebola virus infections

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 06/24/16 - 05/31/17
PI: John D Williams

? DESCRIPTION (provided by applicant): Ebola virus (EBOV) is a member of the filovirus family that causes severe viral hemorrhagic fever (VHF). Although infrequent, epidemics of EBOV can cause high mortality rates of up to 90%; the subsequent medical and social upheaval can be widespread and severe, as seen in the recent outbreak in Western Af...

$982K

Novel spectinamide antibiotics for the treatment of MDR/XDR tuberculosis

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 06/01/16 - 05/31/17
PI: Michelle M. Butler

DESCRIPTION (provided by applicant): The overall objective of this project is to develop a novel chemical class of tuberculosis (TB) therapeutic agents, the spectinamide series, for use against MDR and XDR strains of Mycobacterium tuberculosis (Mtb) and identify, through a series of in vivo efficacy assays and preclinical pharmacokinetics, toxic...

$287K

Antibiotic potentiators maximizing the formation of open- channel OprF-type outer membrane porins

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 06/01/16 - 05/31/17
PI: Donald T Moir

? DESCRIPTION (provided by applicant): The overall goal of this project is to address the critical medical need for agents to combat antibacterial drug resistance by a novel approach of potentiating drug influx in Gram-negative non-fermenters such as Pseudomonas aeruginosa and Acinetobacter baumannii. These species exhibit intrinsic drug resis...

$288K

Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 03/01/16 - 02/28/17
PI: LIJUN RONG

? DESCRIPTION (provided by applicant): Ebola (EBOV) and Marburg (MARV) viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of 4-14 days. Because of the safety concerns, these viruses are designated as biosafety level 4 agents. Currently there ...

$783K

Optimization of novel pyranopyridine efflux pump inhibitors

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 02/01/16 - 01/31/17
PI: Timothy J Opperman

? DESCRIPTION (provided by applicant): Multi-drug resistance (MDR) in Gram-negative pathogens, including the Enterobacteriaceae and Pseudomonas aeruginosa, poses a significant threat to our ability to effectively treat infections caused by these organisms. A major component in the development of the MDR phenotype in Gram-negative bacteria is ...

$288K

Lipoprotein synthesis inhibitors for multi-drug resistant Gram-negative therapy

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 02/01/16 - 01/31/17
PI: TOMAS MAIRA-LITRAN

? DESCRIPTION (provided by applicant): The increasing prevalence of drug-resistant bacterial infections highlights the critical medical need for new agents that are not susceptible to existing resistance mechanisms. Few new agents are in development for Gram-negative bacteria, which take up small molecules sparingly and efflux most compounds ...

$690K

Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 01/01/16 - 12/31/16
PI: Michelle M. Butler

DESCRIPTION (provided by applicant): The overall objective of this project is to generate new, potent, selective antimalarials that act through a novel mechanism of blocking the plasmodial surface anion channel (PSAC), a previously unexploited and highly conserved plasmodial target. Human malaria is caused by five species of protozoan parasites ...

$299K

GPCR antagonists as anti-Ebola virus entry inhibitors

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 08/01/15 - 07/31/16
PI: LIJUN RONG

DESCRIPTION (provided by applicant): Ebola (EBOV) and Marburg (MARV) viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of 4-14 days. Because of the safety concerns, these viruses are designated as biosafety level 4 agents. Currently there is no...

$295K

Small Molecule Inhibitors of trans-Translation with Broad Spectrum Antibacterial

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 07/01/15 - 06/30/16
PI: John D Williams

DESCRIPTION (provided by applicant): Because of the emergence of resistance to known antibiotics, there is a critical need for new antibacterial agents, especially against Gram-negative pathogens. trans-Translation is a biochemical pathway that is essential to many bacterial species, including Neisseria gonorrhoeae, Shigella flexneri, and Mycopl...

Load More